Disease Modifying Monoclonal Antibodies and Symptomatic Pharmacological Treatment for Alzheimer’s Disease DOI Creative Commons
Xiaoming Qi, Damir Nizamutdinov, Sheng‐Han Yi

et al.

Biomedicines, Journal Year: 2024, Volume and Issue: 12(11), P. 2636 - 2636

Published: Nov. 19, 2024

Alzheimer's Disease (AD) is an irreversible, progressive syndrome characterized by neurocognitive impairment. Two neuropathological features seen in AD are extracellular amyloid plaques consisting of beta1-40 and 1-42, intracellular neurofibrillary tangles (NFTs). For decades, neuroscience research has heavily focused on seeking to understand the primary mechanism searching for pharmacological approaches treatment dementia. Three monoclonal antibodies that act against beta-aducanumab, lecanemab, donanemab-have been approved Food Drug Administration (FDA) mild cognitive impairment AD, addition medications symptom management such as acetylcholinesterase inhibitors N-methyl-D-aspartate (NMDA) antagonist. Further trials should focus combination therapies targeting tau pathology.

Language: Английский

Echoes in the night: How sleep quality influences auditory health DOI
Peng Zhang, Xiaogang An,

Runqin Yang

et al.

Neuroscience, Journal Year: 2025, Volume and Issue: unknown

Published: April 1, 2025

Language: Английский

Citations

0
Disease Modifying Monoclonal Antibodies and Symptomatic Pharmacological Treatment for Alzheimer’s Disease DOI Creative Commons
Xiaoming Qi, Damir Nizamutdinov, Sheng‐Han Yi

et al.

Biomedicines, Journal Year: 2024, Volume and Issue: 12(11), P. 2636 - 2636

Published: Nov. 19, 2024

Alzheimer's Disease (AD) is an irreversible, progressive syndrome characterized by neurocognitive impairment. Two neuropathological features seen in AD are extracellular amyloid plaques consisting of beta1-40 and 1-42, intracellular neurofibrillary tangles (NFTs). For decades, neuroscience research has heavily focused on seeking to understand the primary mechanism searching for pharmacological approaches treatment dementia. Three monoclonal antibodies that act against beta-aducanumab, lecanemab, donanemab-have been approved Food Drug Administration (FDA) mild cognitive impairment AD, addition medications symptom management such as acetylcholinesterase inhibitors N-methyl-D-aspartate (NMDA) antagonist. Further trials should focus combination therapies targeting tau pathology.

Language: Английский

Citations

1